Vienna, Austria
Vienna, Austria

Time filter

Source Type

Patent
Arsanis Biosciences Gmbh | Date: 2016-12-09

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.


Patent
ARSANIS Biosciences GmbH | Date: 2017-05-17

The subject relates to an isolated O25b antigen of multi drug resistant (MDR) E. coli strains and immunogens or vaccines containing the same.


Patent
Arsanis Biosciences Gmbh | Date: 2014-12-19

The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.


Patent
ARSANIS Biosciences GmbH | Date: 2017-06-21

The invention relates to a method for the prediction of S. aureus disease in a subject heavily colonized by S. aureus but not showing any symptom of S. aureus disease, said method comprising the step of determining the alpha haemolysin level in a biological sample of said subject as compared to a standard or reference control, wherein an elevated alpha haemolysin level or activity is indicative of the onset of S. aureus disease.


The subject relates to an isolated Staphylococcus aureus leukocidin antigen comprising a LukGH complex, an antibody specifically binding to the Luk GH complex, and the human CD11b/CD18 complex for use in a method of determining the binding or toxicity of the Staphylococcus aureus Luk GH bi-component cytolysin.


Patent
Arsanis Biosciences Gmbh | Date: 2013-04-17

The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.


Patent
ARSANIS Biosciences GmbH | Date: 2014-01-17

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.


The invention provides for an antibody comprising at least one binding site that specifically binds to a LukGH complex, which antibody comprises at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in Table 1, or functionally active CDR variants thereof.


Patent
Arsanis Biosciences Gmbh | Date: 2014-10-17

The invention refers to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, which antibody comprises at least three complementarity determining regions (CDR1 to CDR3) of the antibody heavy chain variable region (VH), wherein A) the antibody comprises a) a CDR1 comprising or consisting of the amino acid sequence YSISSGMGWG (SEQ ID 1); and b) a CDR2 comprising or consisting of the amino acid sequence SIDQRGSTYYNPSLKS (SEQ ID 2); and c) a CDR3 comprising or consisting of the amino acid sequence ARDAGHGVDMDV (SEQ ID 3); or B) the antibody comprises at least one functionally active CDR variant of a) the parent CDR1 consisting of the amino acid sequence of SEQ ID 1; or b) the parent CDR2 consisting of the amino acid sequence of SEQ ID 2; or c) the parent CDR3 consisting of the amino acid sequence of SEQ ID 3; wherein the functionally active CDR variant comprises at least one point mutation in the parent CDR sequence, and comprises or consists of the amino acid sequence that has at least 60% sequence identity with the parent CDR sequence. It further refers to such cross-neutralizing antibody which is a functionally active variant antibody of a parent antibody that comprises a polyspecific binding site of the VH amino acid sequence of SEQ ID 20, and the VL amino acid sequence of SEQ ID 39, which functionally active variant antibody comprises at least one point mutation in any of the framework regions (FR) or constant domains, or complementarity determining regions (CDR1 to CDR6) in any of SEQ ID 20 or SEQ 39, and has an affinity to bind each of the toxins with a Kd of less than 10^(8)M, preferably less than 10^(9)M.


Grant
Agency: European Commission | Branch: H2020 | Program: SME-1 | Phase: PHC-12-2014-1 | Award Amount: 71.43K | Year: 2014

Hospital acquired infections such as ventilator associated pneumonia (VAP) are associated with unacceptably high mortality rates and spiraling healthcare costs. Staphylococcus aureus (S. aureus) is a major human pathogen, and one of the leading causes of VAP and other nosocomial infections. Vital to the effective management and treatment of S. aureus VAP is the use of appropriate antimicrobial therapies, and ideally prophylactic measures. Antibiotic stewardship efforts, aimed to reduce the spread of antibiotic resistance, are resulting in changing clinical guidelines so the causative pathogen is identified before antibiotic treatment is initiated. Such approaches rely on diagnostic measures to identify the infecting bacteria and resistance pattern, and usually take over 24 hours to complete. Therefore, early identification of patients at risk of developing VAP coupled with characterization of the causative pathogen would allow early treatment and potential prevention, ultimately translating to reduced mortality and healthcare cost. The overall aim of this project is the clinical validation of a novel biomarker identified by Arsanis Biosciences to identify patients likely to develop S. aureus induced VAP. In parallel, we aim to develop a unique rapid diagnostic test incorporating this biomarker and detecting other markers to characterize the bacteria, for use to at the bedside to identify these at risk patients in the intensive care unit (ICU). The test is aimed to give the ICU clinician rapid information to inform early clinical intervention. During the feasibility study we will assess the market and clinical utility of the diagnostic test through dialogue with KOLs, healthcare professionals and end users from a range of EU hospitals. We will also validate the format and design of the diagnostic kit, and design a road-map for clinical study and approval. We will also assess pricing and reimbursement issues and complete FTO analysis for the concept.

Loading Arsanis Biosciences GmbH collaborators
Loading Arsanis Biosciences GmbH collaborators